HemaSphere (Apr 2023)
Obinutuzumab Can Be Administered as a 90-minute Short Duration Infusion in Patients With Previously Untreated Follicular Lymphoma: GAZELLE End of Induction Analysis
- Miguel A. Canales,
- Thomas A. Buchholz,
- Jaisson A.P. Bortolini,
- Laura M. Fogliatto,
- Takayuki Ishikawa,
- Koji Izutsu,
- Antonio Salar,
- Jeff P. Sharman,
- Dirk Klingbiel,
- Sunny Pokala,
- Ekaterina Vorozheikina,
- Peter Trask,
- Joana Parreira,
- Kai Hübel
Affiliations
- Miguel A. Canales
- 1 Hospital Universitario La Paz, Madrid, Spain
- Thomas A. Buchholz
- 2 Scripps MD Anderson Cancer Center, San Diego, CA, USA
- Jaisson A.P. Bortolini
- 3 Centro de Pesquisas Oncologicas, Florianopolis, Brazil
- Laura M. Fogliatto
- 4 Hospital de Clínicas de Porto Alegre, Porto Alegre, Brazil
- Takayuki Ishikawa
- 5 Kobe City Medical Center, General Hospital, Hyogo, Japan
- Koji Izutsu
- 6 National Cancer Center Hospital, Tokyo, Japan
- Antonio Salar
- 7 Hospital del Mar, Barcelona, Spain
- Jeff P. Sharman
- 8 Willamette Valley Cancer Institute and Research Center, US Oncology Research, Eugene, OR, USA
- Dirk Klingbiel
- 9 F. Hoffmann-La Roche Ltd, Basel, Switzerland
- Sunny Pokala
- 9 F. Hoffmann-La Roche Ltd, Basel, Switzerland
- Ekaterina Vorozheikina
- 10 IQVIA Medical and Scientific Services, Moscow, Russia
- Peter Trask
- 11 Genentech, Inc., South San Francisco, CA, USA
- Joana Parreira
- 9 F. Hoffmann-La Roche Ltd, Basel, Switzerland
- Kai Hübel
- 12 Uniklinik Köln, Department I of Internal Medicine, Cologne, Germany
- DOI
- https://doi.org/10.1097/HS9.0000000000000860
- Journal volume & issue
-
Vol. 7,
no. 4
p. e860
Abstract
No abstracts available.